Business
Lantern Pharma Reports Third Quarter 2022 Financial Results and Operational Highlights
The Harmonic™ clinical trial activated the first two clinical trial sites for a Phase 2 study in never-smoker patients with non-small lung cancer and
About this update from Lantern Pharma Inc.
[{"type":"text","content":"\n\nThe Harmonic™ clinical trial activated the first two clinical trial sites for a Phase 2 study in never-smoker patients with non-small lung cancer and anticipates multiple additional sites in the US during 2022\n\n\nIND-enabling studies for both LP-184 and LP-284 are expected to be complete in Q1 2023\n\n\nFirst in human Phase 1 clinical trials for both LP-184 and LP-284 drug candidates are targeted for launch in first half of 2023\n\n\nIntellectual property (IP) estate was strengthened with the addition of a new issued patent for LP-300 uses\n\n\nRADR®, a drug development platform focused on oncology and leveraging artificial intelligence, is ahead of schedule for both datapoint and functional module expansion\n\n\n$57.8 million in cash, cash equivalents, and marketable securities as of September 30, 2022\n\n\nA net decrease of $4.3 million in cash, cash equivalents, and marketable securities occurred during the three months ended September 30, 2022\n\n\nLantern has a cash runway into 2025\n\n\nConference call scheduled for 4:30 p.m. ET / 1:30 p.m. PT today\n\n\n DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (\"A.I.\") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the third quarter ended September 30, 2022.\n\n“Leveraging large scale biomarker and clinical data, machine learning and artificial intelligence to fundamentally transform the cost, timeline and risk in developing oncology medicines has been the focus of Lantern. We are now advancing two drug-candidates in the Phase 2 clinical stage, and expect to launch two additional drug-candidates into first in human clinical trials in early 2023. We have rapidly advanced our new drug-candidates, LP-184 and LP-284, and been focused on advancing our rescued drug-candidates, LP-100 and LP-300 towards precise and meaningful treatment indications. Also, we have several additional therapeutic programs that we expect to introduce in the coming quarters with both our existing molecules and with new molecules and combinations that we have been validating with both AI-guided development and in highly targeted wet-lab studies,” stated P...